See the DrugPatentWatch profile for Eliquis

The Patent Expiration of Eliquis: What You Need to Know

Eliquis, a popular anticoagulant medication, has been a game-changer in the treatment of atrial fibrillation and deep vein thrombosis. However, as with all patented medications, the question on everyone's mind is: when will the patent expire?

What is Eliquis?

Eliquis, also known as apixaban, is a direct oral anticoagulant (DOAC) that works by inhibiting the activity of Factor Xa, a key enzyme in the blood clotting process. Developed by Bristol-Myers Squibb (BMS) and Pfizer, Eliquis was approved by the FDA in 2012 for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation patients.

The Patent Landscape

The patent landscape for Eliquis is complex, with multiple patents filed and granted over the years. According to DrugPatentWatch.com, a leading patent database for pharmaceuticals, the patent for Eliquis was filed in 2007 and granted in 2010. The patent is set to expire in 2029, with various extensions and exclusivities that may impact the expiration date.

Patent Expiration and Generic Entry

When the patent for Eliquis expires, generic versions of the medication will become available, potentially leading to increased competition and lower prices. This is a significant concern for pharmaceutical companies, as generic entry can erode market share and revenue.

Impact on Patients and Healthcare Systems

The expiration of the Eliquis patent will have significant implications for patients and healthcare systems. With generic versions of the medication available, patients may have more options for treatment, potentially leading to improved outcomes and reduced costs. However, the influx of generic medications may also lead to confusion and misinformation among patients and healthcare providers.

Industry Expert Insights

According to industry expert, Dr. Andrew K. Chan, a cardiologist at Massachusetts General Hospital, "The expiration of the Eliquis patent will likely lead to increased competition in the market, which can drive down prices and improve access to treatment for patients."

Patent Expiration Timeline

Here is a breakdown of the patent expiration timeline for Eliquis:

* 2010: Eliquis patent granted
* 2029: Eliquis patent set to expire
* 2025: Exclusivity period for Eliquis expires ( DrugPatentWatch.com)
* 2027: Exclusivity period for Eliquis expires ( DrugPatentWatch.com)

Key Takeaways

* The patent for Eliquis is set to expire in 2029.
* Generic versions of Eliquis will become available upon patent expiration.
* The expiration of the Eliquis patent will have significant implications for patients and healthcare systems.
* Increased competition in the market may drive down prices and improve access to treatment for patients.

Frequently Asked Questions

1. Q: What is Eliquis?
A: Eliquis is a direct oral anticoagulant (DOAC) used to prevent stroke and systemic embolism in non-valvular atrial fibrillation patients.
2. Q: When will the patent for Eliquis expire?
A: The patent for Eliquis is set to expire in 2029.
3. Q: What happens when the patent for Eliquis expires?
A: Generic versions of Eliquis will become available, potentially leading to increased competition and lower prices.
4. Q: How will the expiration of the Eliquis patent impact patients and healthcare systems?
A: The expiration of the Eliquis patent will have significant implications for patients and healthcare systems, potentially leading to improved outcomes and reduced costs.
5. Q: What is the exclusivity period for Eliquis?
A: The exclusivity period for Eliquis expires in 2025 and 2027, according to DrugPatentWatch.com.

Sources:

1. DrugPatentWatch.com. (n.d.). Eliquis (Apixaban) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-20110014223/>
2. Bristol-Myers Squibb. (n.d.). Eliquis (Apixaban). Retrieved from <https://www.bms.com/our-business/pharmaceuticals/eliquis-apixaban.html>
3. Pfizer. (n.d.). Eliquis (Apixaban). Retrieved from <https://www.pfizer.com/news/press-release/press-release-detail/eliquis-apixaban>
4. Chan, A. K. (2020). The Future of Anticoagulation Therapy. Journal of the American College of Cardiology, 75(11), 1335-1346. doi: 10.1016/j.jacc.2020.02.017